Published in J Neural Transm (Vienna) on February 04, 2008
Candidate gene studies of ADHD: a meta-analytic review. Hum Genet (2009) 3.56
DNA variation in the SNAP25 gene confers risk to ADHD and is associated with reduced expression in prefrontal cortex. PLoS One (2013) 0.86
Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry (2012) 0.85
Association study of SNAP25 and schizophrenia in Irish family and case-control samples. Am J Med Genet B Neuropsychiatr Genet (2010) 0.81
DIRAS2 is associated with adult ADHD, related traits, and co-morbid disorders. Neuropsychopharmacology (2011) 0.80
Association of SNAP-25 Gene Ddel and Mnll Polymorphisms with Adult Attention Deficit Hyperactivity Disorder. Psychiatry Investig (2014) 0.78
SNARE complex in developmental psychiatry: neurotransmitter exocytosis and beyond. J Neural Transm (Vienna) (2016) 0.78
The role of ASTN2 variants in childhood and adult ADHD, comorbid disorders and associated personality traits. J Neural Transm (Vienna) (2016) 0.75
PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet (1998) 23.25
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04
The synaptic vesicle cycle. Annu Rev Neurosci (2004) 12.25
Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 7.94
PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics (2005) 5.14
SNARE complex formation is triggered by Ca2+ and drives membrane fusion. Cell (1999) 3.04
Transmission/disequilibrium tests using multiple tightly linked markers. Am J Hum Genet (2000) 2.45
A powerful strategy to account for multiple testing in the context of haplotype analysis. Am J Hum Genet (2004) 2.07
The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am (2001) 1.50
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess (2006) 1.49
Expression and function of SNAP-25 as a universal SNARE component in GABAergic neurons. J Neurosci (2006) 1.38
Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatry (2000) 1.31
Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods (2006) 1.28
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. Mol Psychiatry (2002) 1.24
Family-based association analysis with tightly linked markers. Hum Hered (2003) 1.24
The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 1.22
Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry (2006) 1.17
New potential leads in the biology and treatment of attention deficit-hyperactivity disorder. Curr Opin Neurol (2007) 1.16
Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res (1991) 1.15
Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol Psychiatry (2003) 1.12
Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J Neurosci (1996) 1.10
The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. Mol Psychiatry (2005) 1.10
Haplotype analysis of SNAP-25 suggests a role in the aetiology of ADHD. Mol Psychiatry (2004) 1.05
Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev (2000) 0.99
Abnormal latent inhibition and impulsivity in coloboma mice, a model of ADHD. Neurobiol Dis (2006) 0.91
Molecular genetic aspects of attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev (2004) 0.88
Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant. Pharmacol Biochem Behav (2001) 0.87
Multimethod psychoeducational intervention for preschool children with disruptive behavior: two-year post-treatment follow-up. J Abnorm Child Psychol (2000) 0.84
Preschool children with disruptive behavior: three-year outcome as a function of adaptive disability. Dev Psychopathol (2002) 0.81
Transgenic rescue of SNAP-25 restores dopamine-modulated synaptic transmission in the coloboma mutant. Brain Res (1999) 0.80
DNA pooling analysis of ADHD and genes regulating vesicle release of neurotransmitters. Am J Med Genet B Neuropsychiatr Genet (2005) 0.78
[Genetic findings in Attention-Deficit and Hyperactivity Disorder (ADHD)]. Z Kinder Jugendpsychiatr Psychother (2006) 0.77
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Theoretical uncertainty of measurements using quantitative polymerase chain reaction. Biophys J (1996) 3.30
Pharmacogenetic prediction of clozapine response. Lancet (2000) 3.10
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol (1998) 2.94
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry (2002) 2.85
Serotonin transporter gene polymorphism, differential early rearing, and behavior in rhesus monkey neonates. Mol Psychiatry (2002) 2.65
A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60
Identification of and spatio-temporal differences between microbial assemblages from two neighboring sulfurous lakes: comparison by microscopy and denaturing gradient gel electrophoresis. Appl Environ Microbiol (2000) 2.51
[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50
Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J (1997) 2.33
A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatry (2001) 2.27
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 2.22
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 2.19
Influence of lipid/peptide hydrophobic mismatch on the thickness of diacylphosphatidylcholine bilayers. A 2H NMR and ESR study using designed transmembrane alpha-helical peptides and gramicidin A. Biochemistry (1998) 2.07
Exclusion of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene as a candidate for catatonic schizophrenia in a large family supporting the chromosome 15q13-22 locus. Mol Psychiatry (2002) 2.01
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98
The utility of the non-human primate; model for studying gene by environment interactions in behavioral research. Genes Brain Behav (2003) 1.91
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83
Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest (2000) 1.80
Validity of western immunoblot band patterns in the serodiagnosis of Lyme borreliosis. J Clin Microbiol (1991) 1.79
HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med (1997) 1.69
Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun (1998) 1.69
Inhibitory sites in enzymes: zinc removal and reactivation by thionein. Proc Natl Acad Sci U S A (1999) 1.68
Necrotizing lymphadenitis: Kikuchi--Fujimoto disease alias lupus lymphadenitis? Lupus (2009) 1.67
Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur J Immunol (1991) 1.67
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry (2010) 1.61
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium [corrected]. J Biotechnol (1992) 1.56
Exploring the genetic link between RLS and ADHD. J Psychiatr Res (2009) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics (2001) 1.53
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci (2000) 1.46
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint]. Zentralbl Chir (1995) 1.44
Pre-hospital discharge testing after implantable cardioverter defibrillator implantation: a measure of safety or out of date? A retrospective analysis of 975 patients. Europace (2011) 1.43
Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia (2010) 1.41
Familial clustering of infantile cirrhosis in Northern Germany: A clue to the etiology of idiopathic copper toxicosis. J Pediatr (1999) 1.39
Systemic effects and side effects of interstitial techniques used in liver tissue. J Am Coll Surg (1999) 1.39
The human serotonin transporter gene polymorphism--basic research and clinical implications. J Neural Transm (Vienna) (1997) 1.39
Visual information processing in dyslexic children. Clin Neurophysiol (2004) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci (2001) 1.34
Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry (2010) 1.33
Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J Neurosci (2001) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Mol Psychiatry (1997) 1.31
Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept (2001) 1.30
Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci (2000) 1.29
A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry (2006) 1.29
The response of the microbial community of marine sediments to organic carbon input under anaerobic conditions. Syst Appl Microbiol (1999) 1.28
First genome-wide association scan on neurophysiological endophenotypes points to trans-regulation effects on SLC2A3 in dyslexic children. Mol Psychiatry (2009) 1.27
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 1.26
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23
Role of Candida albicans in granulomatous tissue reactions. II. In vivo degradation of C. albicans in hepatic macrophages of mice. J Infect Dis (1977) 1.23
The beta-peptide hairpin in solution: conformational study of a beta-hexapeptide in methanol by NMR spectroscopy and MD simulation. J Am Chem Soc (2001) 1.22
Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22
Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells. Oncogene (2001) 1.22
Solid-state NMR determination of the secondary structure of Samia cynthia ricini silk. Nature (2000) 1.21
Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet (1997) 1.21
Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther (1999) 1.20
Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol (1990) 1.20
Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm (Vienna) (2005) 1.19
Structural limitations on the bifunctional intercalation of diacridines into DNA. Biochemistry (1978) 1.19
Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. Mol Psychiatry (2008) 1.18
Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet (2000) 1.17
Impulsive terahertz radiation with high electric fields from an amplifier-driven large-area photoconductive antenna. Opt Express (2010) 1.17
Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand (2001) 1.16